11242017Headline:

Competent Cells Market: Drivers, Restraints, Opportunities, & Challenges

The global competent cells market is projected to reach USD 2.22 billion by 2022 from USD 1.37 billion in 2017, at a CAGR of 10.2%.Globally, the competent cells market is witnessing a high growth due to factors such as advancements in molecular cloning research due to the emergence of new technologies and the growing commercial demand for molecular cloned products and recombinant proteins.

Key players operating in this market are focusing on acquisitions to strengthen their position. For instance, in November 2015, Merck KGaA (Germany) completed the acquisition of Sigma-Aldrich Co. LLC. (Germany) for USD 17 billion. Sigma-Aldrich Co., LLC is one of the key manufacturers of competent cells. In addition, in March 2017, Thermo Fisher Scientific, Inc. (U.S.) collaborated with Cell and Gene Therapy Catapult (CGT Catapult) (U.K.). Similarly, in February 2014, Thermo Fisher Scientific, Inc. acquired Life Technologies, Inc. (U.S.) to enhance its presence in the competent cells market.

Download PDF Brochurehttp://www.marketsandmarkets.com/pdfdownload.asp?id=265815900

The global competent cell is segmented on the basis of type, which includes chemically competent cells and electrocompetent cells. The chemically competent cells segment is expected to account for the largest share of the market in 2017. This large share can be attributed to the rising intensity of research (due to technological advancement) and availability of government support, along with the growing market demand for molecular cloned products. However, the electrocompetent cells segment is expected to grow at the highest CAGR during the forecast period.

On the basis of application, the market is broadly segmented into cloning, protein expression, and other applications. Cloning is expected to command the largest share of this market in 2017. The market is driven by factors such as increasing research on cloning driven by government support and funding. This application segment is further categorized into subcloning & routine cloning, phage display library construction, toxic/unstable DNA cloning, and high-throughput cloning. Similarly, other applications of competent cells include mutagenesis, single-stranded DNA production, lentiviral vector production, and large plasmid transformation.

Based on end user, the competent cells market has been segmented into academic research institutes, contract research organizations (CROs), and pharmaceutical & biotechnology companies. The pharmaceutical & biotechnology companies segment is expected to witness the highest growth during 2017–2022. This is primarily due to the rising investments in research for developing genomics and proteomics-based products.

By region, the competent cells market is divided into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). The North America region is expected to grow at the fastest CAGR during the forecast period. This can be attributed to the increasing intensity of research due to technological advancement and increasing commercial needs for genomic and protein expressed products, in North American countries.

Emerging market such as Brazil, Russia, India, and China are expected to present significant opportunities for the growth of the competent cells market. Also, emerging applications of competent cells are key opportunities for this market to grow. Other applications of competent cells, such as lentiviral vector production, mutagenesis, and large plasmid transformation, have emerged in the last few years. Considering the growth prospects of these emerging application segments, some companies are offering technologically advanced products for lentiviral vector production, mutagenesis, and large plasmid transformation. For instance, Lucigen (U.S.) launched Endura electrocompetent cells, which are highly recommended by researchers for lentiviral libraries of CRISPR clones, particularly the GeCKO v2.0 plasmid libraries (REF). Similarly, OriGene Technologies, Inc. (U.S.) offers CRISPR/Cas9-based kits.

What Next?

Recent Articles